Praxis Precision Medicines is a pre-revenue biotech with a binary risk profile, evidenced by zero product revenue in 2026 versus $7.5M collaboration revenue in 2024Q4. The company's escalating R&D burn, up 157% from 2024Q1 to 2026Q2, and negative operating lev...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue collapsed to zero in 2026 from $7.5M in 2024Q4, while R&D expenses surged 157% to $69.4M, driving operating losses to -$96.9M in 2026Q2.
The consensus price target of $607.15 represents a potential upside of +127.8% from the current trading price of $266.54.
Praxis is positioned to deliver significant commercial catalysts in 2026, supported by a robust financial runway.
The biotechnology sector is experiencing a thaw in capital markets, with selective investment flowing to scientifically robust companies like Praxis.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$2.87+21.8% vs -$3.67 | — vs $1M |
Q2 2026 May 7, 2026 | -$3.20+10.6% vs -$3.58 | — vs $100,000 |
Q1 2026 Feb 19, 2026 | -$3.50-12.0% vs -$3.13 | — vs $66,667 |
Q4 2025 Nov 5, 2025 | -$3.36+2.6% vs -$3.45 | — vs $256,090 |
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and three have issued a strong buy rating
Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, sixteen have given a buy rating and four have given a
Benchmark PRAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Praxis Precision Medicines, Inc. (PRAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $282.12 | $7.87B | -20.93 | -100% | — | -45.83% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $23.88 | $2.07B | -7.83 | 53.95% | -928.44% | -76.09% | — | |
| $7.83 | $505.2M | -6.12 | -0.3% | 2.94% | 1.91% | — | |
| $298.41 | $5.98B | 48.68 | 60.4% | 67.88% | 20.06% | — | |
| $2.57 | $479.66M | -10.71 | 1181.27% | -2178.9% | -23.64% | — |
Praxis Precision Medicines, Inc. (PRAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Praxis Precision Medicines, Inc. (PRAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 7, 2026·SEC
Jul 2, 2026·SEC
Get notified when PRAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Praxis Precision Medicines, Inc. (PRAX) stock FAQ — growth, dividends, profitability & financials explained
Praxis Precision Medicines, Inc. (PRAX) saw revenue decline by 100.0% over the past year.
Praxis Precision Medicines, Inc. (PRAX) reported a net loss of $339.1M for fiscal year 2025.
Praxis Precision Medicines, Inc. (PRAX) has a return on equity (ROE) of -45.8%. Negative ROE indicates the company is unprofitable.
Praxis Precision Medicines, Inc. (PRAX) had negative free cash flow of $306.0M in fiscal year 2025, likely due to heavy capital investments.
